Lakefront Biotherapeutics (LKFT) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Viridian Therapeutics (VRDN) has outperformed Lakefront Biotherapeutics (LKFT) over the past year, losing 14.4% versus a loss of 14.5%. Over five years, VRDN leads with a +9.3% price change compared with -44.9% for LKFT. Viridian Therapeutics is the larger company by market cap ($2.11 billion vs $1.95 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LKFT | VRDN |
|---|---|---|
| Share price | $29.73 | $18.66 |
| Market cap | $1.95B | $2.11B |
| 1-day change | +0.75% | +1.74% |
| YTD return | -9.76% | -40.04% |
| 1-year return | -14.46% | -14.44% |
| 5-year return | -44.86% | +9.31% |
| P/E ratio (TTM) | 2.80 | — |
| EPS (TTM) | $10.60 | $-3.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $70.85M |
| Revenue growth (YoY) | — | +23359.93% |
| Net income (latest FY) | — | $-342.60M |
| Operating margin | — | -512.91% |
| Net margin | — | -483.57% |
| 52-week high | $36.24 | $34.29 |
| 52-week low | $25.68 | $13.18 |
| Distance from 52-week high | -17.96% | -45.58% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +1.51% | +96.95% |
| Average volume | 275.47K | 1.71M |
| Shares outstanding | 65.48M | 113.29M |
| Employees | 196 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Lakefront Biotherapeutics
LKFT stock →Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
LKFT vs VRDN FAQ
Which is bigger, Lakefront Biotherapeutics or Viridian Therapeutics?
Viridian Therapeutics (VRDN) is larger, with a market capitalization of $2.11B compared with $1.95B for Lakefront Biotherapeutics (LKFT).
Which stock has performed better over the past year, LKFT or VRDN?
VRDN returned -14.44% over the past 12 months, compared with -14.46% for LKFT (price return, excluding dividends). Past performance does not predict future results.
Are Lakefront Biotherapeutics and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.